Colin Lightfoot

Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

Articles from Colin

Study demonstrates effectiveness of two doses of BBV152 vaccine against COVID-19

Study demonstrates effectiveness of two doses of BBV152 vaccine against COVID-19

An assessment of potential epitopes in SARS-CoV-2 structural proteins

An assessment of potential epitopes in SARS-CoV-2 structural proteins

The antimicrobial properties of the lungfish cocoon

The antimicrobial properties of the lungfish cocoon

Markers of SARS-CoV-2 shedding in vaccinated and unvaccinated individuals

Markers of SARS-CoV-2 shedding in vaccinated and unvaccinated individuals

Spread and evolution of SARS-CoV-2 lineages with possible recombination events

Spread and evolution of SARS-CoV-2 lineages with possible recombination events

Predicting the capacity of mammal species to become zoonotic SARS-CoV-2 hosts

Predicting the capacity of mammal species to become zoonotic SARS-CoV-2 hosts

Viral biomolecular condensation

Viral biomolecular condensation

What is the global prevalence of long COVID?

What is the global prevalence of long COVID?

Simulating SARS-CoV-2 transmission dynamics for reopening European universities

Simulating SARS-CoV-2 transmission dynamics for reopening European universities

Evidence of significantly greater protection against COVID from BNT162b2 boosters

Evidence of significantly greater protection against COVID from BNT162b2 boosters